Amalgamated Bank’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Amalgamated Bank’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,851	Closed	-$3K	–	3222
2023 Q1	$3K	Sell	10,851 -778	-7%	-$703	﹤0.01%	2931
2022 Q4	$14K	Hold	11,629	–	–	﹤0.01%	2833
2022 Q3	$24K	Buy	+11,629	New	+$19.7K	﹤0.01%	2769

Amalgamated Bank's PEAR Position: Q2 2023 in Review

Amalgamated Bank sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 10,851 shares — an estimated $3K sold.

Amalgamated Bank first reported a position in PEAR in Q3 2022 and held it in 3 quarters. The position peaked at $24K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Amalgamated Bank reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Amalgamated Bank sold 10,851 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $3K.
Amalgamated Bank first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 3 quarters.
Amalgamated Bank's Pear Therapeutics, Inc. Class A Common Stock position peaked at $24K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Amalgamated Bank's 13F filing for Q2 2023, filed 11 Aug 2023.